Active axial spondyloarthritis: potential role of certolizumab pegol

References

• CawleyMIChalmersTMKellgrenJHBallJDestructive lesions of vertebral bodies in ankylosing spondylitisAnn Rheum Dis19723153453584116083
   PubMed Web of Science ®Google Scholar
• BaetenDBrebanMLoriesRSchettGSieperJAre spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype?Arthritis Rheum2013651122023288559
   PubMedGoogle Scholar
• RudwaleitMvan der HeijdeDLandeweRThe development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selectionAnn Rheum Dis200968677778319297344
   PubMed Web of Science ®Google Scholar
• AkkocNKhanMEpidemiology of ankylosing spondylitis and related spondyloarthropathiesWeismanMHReveilleJDVan der HeijdeDAnkylosing Spondylitis and the SpondyloarthropathiesPhiladelphia, PA, USAMosby Elsevier2006
   Google Scholar
• BaklandGNossentHCGranJTIncidence and prevalence of ankylosing spondylitis in Northern NorwayArthritis Rheum200553685085516342091
   PubMed Web of Science ®Google Scholar
• KhanMAEpidemiology of HLA-B27 and arthritisClin Rheumatol199615Suppl 110128835494
   PubMedGoogle Scholar
• WardMMQuality of life in patients with ankylosing spondylitisRheum Dis Clin North Am19982448158279891712
   PubMed Web of Science ®Google Scholar
• WardMMKuzisSRisk factors for work disability in patients with ankylosing spondylitisJ Rheumatol200128231532111246669
   PubMed Web of Science ®Google Scholar
• BaklandGGranJTNossentJCIncreased mortality in ankylosing spondylitis is related to disease activityAnn Rheum Dis201170111921192521784726
   PubMed Web of Science ®Google Scholar
• DougadosMDijkmansBKhanMMaksymowychWvan der LindenSBrandtJConventional treatments for ankylosing spondylitisAnn Rheum Dis200261Suppl 3iii40iii5012381510
   PubMedGoogle Scholar
• KraagGStokesBGrohJHelewaAGoldsmithCThe effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis – a randomized controlled trialJ Rheumatol19901722282332181127
   PubMed Web of Science ®Google Scholar
• BallJEnthesopathy of rheumatoid and ankylosing spondylitisAnn Rheum Dis19713032132234103800
   PubMed Web of Science ®Google Scholar
• BraunJAnkylosing spondylitis: pathology and pathogenesisKlippelJStoneJCroffordLWhitePPrimer on the Rheumatic Diseases13th edNew York, NY, USASpringer2008
   Google Scholar
• FitzGeraldOMcInnesISpondyloarthropathy: disease at the crossroads of immunityBest Pract Res Clin Rheumatol200620594996716980217
   PubMed Web of Science ®Google Scholar
• AppelHKuhneMSpiekermannSImmunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrowArthritis Rheum20065461805181316736521
   PubMed Web of Science ®Google Scholar
• FrancoisRJNeureLSieperJBraunJImmunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced casesAnn Rheum Dis200665671372016249231
   PubMed Web of Science ®Google Scholar
• NeidhartMBaraliakosXSeemayerCExpression of cathepsin K and matrix metalloproteinase 1 indicate persistent osteodestructive activity in long-standing ankylosing spondylitisAnn Rheum Dis20096881334133918678577
   PubMed Web of Science ®Google Scholar
• BaetenDDemetterPCuvelierCComparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activityAnn Rheum Dis2000591294595311087697
   PubMed Web of Science ®Google Scholar
• BaetenDKruithofEDe RyckeLDiagnostic classification of spondylarthropathy and rheumatoid arthritis by synovial histopathology: a prospective study in 154 consecutive patientsArthritis Rheum20045092931294115457462
   PubMed Web of Science ®Google Scholar
• YeremenkoNNoordenbosTCantaertTDisease-specific and inflammation-independent stromal alterations in spondylarthritis synovitisArthritis Rheum201365117418522972410
   PubMedGoogle Scholar
• BaetenDDemetterPCuvelierCAMacrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathyJ Pathol2002196334335011857499
   PubMed Web of Science ®Google Scholar
• NoordenbosTYeremenkoNGofitaIInterleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritisArthritis Rheum20126419910921968742
   PubMed Web of Science ®Google Scholar
• ChatzikyriakidouAGeorgiouIVoulgariPVDrososAAThe role of tumor necrosis factor (TNF)-alpha and TNF receptor polymorphisms in susceptibility to ankylosing spondylitisClin Exp Rheumatol200927464564819772798
   PubMed Web of Science ®Google Scholar
• van der LindenSValkenburgHACatsAEvaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteriaArthritis Rheum19842743613686231933
   PubMed Web of Science ®Google Scholar
• van der HeijdeDSieperJMaksymowychWP2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritisAnn Rheum Dis201170690590821540200
   PubMed Web of Science ®Google Scholar
• ToussirotECurrent therapeutics for spondyloarthritisExpert Opin Pharmacother201112162469247721988214
   PubMed Web of Science ®Google Scholar
• HaroonNInmanRDLearchTJThe impact of TNF-inhibitors on radiographic progression in ankylosing spondylitisArthritis Rheum201365102645265423818109
   PubMed Web of Science ®Google Scholar
• KroonFLandeweRDougadosMvan der HeijdeDContinuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitisAnn Rheum Dis201271101623162922532639
   PubMed Web of Science ®Google Scholar
• SongIHPoddubnyyDARudwaleitMSieperJBenefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugsArthritis Rheum200858492993818383378
   PubMed Web of Science ®Google Scholar
• BraunJvan den BergRBaraliakosX2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitisAnn Rheum Dis201170689690421540199
   PubMed Web of Science ®Google Scholar
• LavieFPavySDernisEPharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinionJoint Bone Spine200774434635217590370
   PubMed Web of Science ®Google Scholar
• MachadoMABarbosaMMAlmeidaAMTreatment of ankylosing spondylitis with TNF blockers: a meta-analysisRheumatol Int20133392199221323686218
   PubMed Web of Science ®Google Scholar
• HaibelHRudwaleitMListingJEfficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-twoArthritis Rheum20085871981199118576337
   PubMed Web of Science ®Google Scholar
• GengenbacherMSebaldHJVilligerPMHofstetterWSeitzMInfliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitisAnn Rheum Dis200867562062417720725
   PubMed Web of Science ®Google Scholar
• KruithofEBaetenDVan den BoschFMielantsHVeysEMDe KeyserFHistological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathyAnn Rheum Dis200564452953615388510
   PubMed Web of Science ®Google Scholar
• BraunJBrandtJListingJTreatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trialLancet200235993131187119311955536
   PubMed Web of Science ®Google Scholar
• RevickiDALuoMPWordsworthPWongRLChenNDavisJCJrATLAS Study GroupAdalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the Adalimumab Trial Evaluating Long-Term Safety and Efficacy for Ankylosing Spondylitis (ATLAS) [published erratum appears in J Rheumatol 2011;38:788]J Rheumatol20083513465318484692
   PubMed Web of Science ®Google Scholar
• Van der HeijdeDDijkmansBGeusensPSieperJDeWoodyKWilliamsonPAnkylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study GroupEfficacy and safety of infliximab in patients with ankylosing spondylitis: results of a andomized, placebo-controlled trial (ASSERT)Arthritis Rheum2005525829115692973
   PubMed Web of Science ®Google Scholar
• BraunJvan der Horst-BruinsmaIEHuangFBurgos-VargasRVlahosBKoenigASClinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trialArthritis Rheum20116315435121630245
   PubMed Web of Science ®Google Scholar
• InmanRDDavisJCJrvan der HeijdeDDiekmanLSieperJKimSIEfficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trialArthritis Rheum2008583402341218975305
   PubMed Web of Science ®Google Scholar
• Van der HeijdeDSalonenDWeissmanBNLandeweRMaksymowychWPKupperHCanadian (M03-606) Study GroupATLAS Study GroupAssessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 yearsArthritis Res Ther200911R12719703304
   PubMed Web of Science ®Google Scholar
• Van der HeijdeDLandeweRBaraliakosXHoubenHvan TubergenAWilliamsonPAnkylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study GroupRadiographic findings following two years of infliximab therapy in patients with ankylosing spondylitisArthritis Rheum20085830637018821688
   PubMed Web of Science ®Google Scholar
• Van der HeijdeDLandeweREinsteinSOryPVosseDNiLRadiographic progression of ankylosing spondylitis after up to two years of treatment with etanerceptArthritis Rheum20085813243118438853
   PubMed Web of Science ®Google Scholar
• GranJTSkomsvollJFThe outcome of ankylosing spondylitis: a study of 100 patientsBr J Rheumatol1997367667719255111
   PubMedGoogle Scholar
• van der HeijdeDDijkmansBGeusensPEfficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)Arthritis Rheum200552258259115692973
   PubMed Web of Science ®Google Scholar
• BaraliakosXListingJFritzCPersistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years – early clinical response predicts long-term outcomeRheumatology (Oxford)20115091690169921672969
   PubMed Web of Science ®Google Scholar
• Marzo-OrtegaHMcGonagleDO’ConnorPEmeryPEfficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging studyArthritis Rheum20014492112211711592375
   PubMed Web of Science ®Google Scholar
• BraunJvan der Horst-BruinsmaIEHuangFClinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trialArthritis Rheum20116361543155121630245
   PubMed Web of Science ®Google Scholar
• SongIHHermannKHaibelHEffects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trialAnn Rheum Dis201170459059621372193
   PubMed Web of Science ®Google Scholar
• NashPTFlorinTHTumour necrosis factor inhibitorsMed J Aust2005183420520816097922
   PubMed Web of Science ®Google Scholar
• SieperJvan der HeijdeDDougadosMEfficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)Ann Rheum Dis201372681582222772328
   PubMed Web of Science ®Google Scholar
• LambertRGSalonenDRahmanPAdalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled studyArthritis Rheum200756124005401418050198
   PubMed Web of Science ®Google Scholar
• InmanRDDavisJCJrHeijdeDEfficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trialArthritis Rheum200858113402341218975305
   PubMed Web of Science ®Google Scholar
• DeeksEDCertolizumab pegol: a review of its use in the management of rheumatoid arthritisDrugs2013731759723338540
   PubMed Web of Science ®Google Scholar
• NesbittAFossatiGBerginMMechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agentsInflamm Bowel Dis200713111323133217636564
   PubMed Web of Science ®Google Scholar
• VeroneseFMPasutGPEGylation, successful approach to drug deliveryDrug Discov Today200510211451145816243265
   PubMed Web of Science ®Google Scholar
• ChapmanAPPEGylated antibodies and antibody fragments for improved therapy: a reviewAdv Drug Deliv Rev200254453154512052713
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationUCBPharmaCimzia (certolizumab pegol) lyophilized powder or solution for subcutaneous use: US prescribing information2012 Available from; http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125160s189lbl.pdfAccessed November 12, 2013
   Google Scholar
• PalframanRAireyMMooreAVuglerANesbittAUse of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritisJ Immunol Methods20093481–2364119567252
   PubMed Web of Science ®Google Scholar
• NesbittAHenryAHigh affinity and potency of the pegylated Fab’ fragment CDP870. Direct comparison with other anti-TNF agentsAm J Gastroenterol200499Suppl 10S253
   Web of Science ®Google Scholar
• SchreiberSKhaliq-KareemiMLawranceICMaintenance therapy with certolizumab pegol for Crohn’s diseaseN Engl J Med2007357323925017634459
   PubMed Web of Science ®Google Scholar
• SchreiberSRutgeertsPFedorakRNA randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s diseaseGastroenterology2005129380781816143120
   PubMed Web of Science ®Google Scholar
• SandbornWJAbreuMTD’HaensGCertolizumab pegol in patients with moderate to severe Crohn’s disease and secondary failure to infliximabClin Gastroenterol Hepatol201088688695. e68220451663
   PubMed Web of Science ®Google Scholar
• SmolenJLandeweRBMeasePEfficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trialAnn Rheum Dis200968679780419015207
   PubMed Web of Science ®Google Scholar
• FleischmannRVencovskyJvan VollenhovenRFEfficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD studyAnn Rheum Dis200968680581119015206
   PubMed Web of Science ®Google Scholar
• KeystoneEHeijdeDMasonDJrCertolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyArthritis Rheum200858113319332918975346
   PubMed Web of Science ®Google Scholar
• ChoyEHHazlemanBSmithMEfficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trialRheumatology (Oxford)200241101133113712364632
   PubMed Web of Science ®Google Scholar
• Ruiz GarciaVJobanputraPBurlsACertolizumab pegol (CDP870) for rheumatoid arthritis in adultsCochrane Database Syst Rev20112CD00764921328299
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGStoinovSCertolizumab pegol for the treatment of Crohn’s diseaseN Engl J Med2007357322823817634458
   PubMed Web of Science ®Google Scholar
• MeasePJFleischmannRDeodharAAEffect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)Ann Rheum Dis10162013 [Epub ahead of print.]
   Google Scholar
• LandeweRBraunJDeodharAEfficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 studyAnn Rheum Dis962013 [Epub ahead of print.]
   Google Scholar